LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: Acquired thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome successfully treated with eculizumab.

    Sasapu, Appalanaidu / Cottler-Fox, Michele / Motwani, Pooja

    Proceedings (Baylor University. Medical Center)

    2017  Volume 30, Issue 2, Page(s) 182–183

    Abstract: ... in two closely related genes, complement factor H-related 1 and complement factor H-related 3. ...

    Abstract Acquired idiopathic thrombotic thrombocytopenic purpura is a life-threatening disease with a mortality of up to 90%, if not promptly recognized and treated. We report a 64-year-old woman with this condition who presented with left-sided weakness and seizure-like activity preceded by headache and easy bruising. She did not achieve optimal response to plasma exchange, corticosteroids, rituximab, and vincristine. We initiated treatment with eculizumab, following which she had durable remission that continued for 30 months after discontinuation of the drug. We later found that our patient has homozygous deletion in two closely related genes, complement factor H-related 1 and complement factor H-related 3.
    Language English
    Publishing date 2017-02-01
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2703932-8
    ISSN 1525-3252 ; 0899-8280
    ISSN (online) 1525-3252
    ISSN 0899-8280
    DOI 10.1080/08998280.2017.11929576
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6987: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Mobilization and collection of autologous hematopoietic progenitor/stem cells.

    Montgomery, Matthew / Cottler-Fox, Michele

    Clinical advances in hematology & oncology : H&O

    2007  Volume 5, Issue 2, Page(s) 127–136

    Abstract: Autologous hematopoietic progenitor/stem cell (HPC) transplantation has become a standard treatment for a wide variety of malignancies. Most HPCs at present are collected from the peripheral blood via leukapheresis following chemotherapy and/or growth ... ...

    Abstract Autologous hematopoietic progenitor/stem cell (HPC) transplantation has become a standard treatment for a wide variety of malignancies. Most HPCs at present are collected from the peripheral blood via leukapheresis following chemotherapy and/or growth factor-mediated mobilization. Several commercial platforms are available to enumerate the circulating levels of CD34+ HPCs. These values can then be used to guide the timing of leukapheresis as well as to measure the success of daily collections. Most mobilization regimens consist of chemotherapy followed by one or more growth factors such as granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, erythropoietin, or AMD3100. Occasionally a subset of patients will prove unable to mobilize effectively enough to collect at least 2 x 106 CD34+ cells/kg, the number of HPCs currently considered to be appropriate for timely engraftment and recovery of hematopoiesis. In this subset of patients, repeat HPC collection or marrow harvest with or without growth factor stimulation may be tried. The importance of the stem cell niche in mobilization, in particular the relationship of osteoblasts and the sympathetic nervous system in the release of HPCs and other cells from the marrow stroma, may lead to entirely different or improved methods of mobilization in the future. Recent research has explored the benefits of using HPCs outside of the oncology arena, notably in the area of cardiac myocyte regeneration following infarction, making the subject of mobilization potentially important to physicians in many areas of medicine.
    MeSH term(s) Hematopoietic Stem Cell Mobilization ; Hematopoietic Stem Cell Transplantation ; Humans ; Neoplasms/therapy ; Transplantation, Autologous ; Treatment Outcome
    Language English
    Publishing date 2007-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion.

    Luo, Yi / Shao, Lijian / Chang, Jianhui / Feng, Wei / Liu, Y Lucy / Cottler-Fox, Michele H / Emanuel, Peter D / Hauer-Jensen, Martin / Bernstein, Irwin D / Liu, Lingbo / Chen, Xing / Zhou, Jianfeng / Murray, Peter J / Zhou, Daohong

    Blood advances

    2018  Volume 2, Issue 8, Page(s) 859–870

    Abstract: Uncovering the cellular and molecular mechanisms by which hematopoietic stem cell (HSC) self-renewal is regulated can lead to the development of new strategies for promoting ex vivo HSC expansion. Here, we report the discovery that alternative (M2)- ... ...

    Abstract Uncovering the cellular and molecular mechanisms by which hematopoietic stem cell (HSC) self-renewal is regulated can lead to the development of new strategies for promoting ex vivo HSC expansion. Here, we report the discovery that alternative (M2)-polarized macrophages (M2-MΦs) promote, but classical (M1)-polarized macrophages (M1-MΦs) inhibit, the self-renewal and expansion of HSCs from mouse bone marrow (BM) in vitro. The opposite effects of M1-MΦs and M2-MΦs on mouse BM HSCs were attributed to their differential expression of nitric oxide synthase 2 (NOS2) and arginase 1 (Arg1), because genetic knockout of
    MeSH term(s) Animals ; Arginase/metabolism ; Cell Proliferation/drug effects ; Cell Self Renewal/drug effects ; Coculture Techniques ; Fetal Blood/cytology ; Hematopoietic Stem Cells/cytology ; Humans ; Macrophages/physiology ; Male ; Mice ; Nitric Oxide Synthase Type II/metabolism
    Chemical Substances Nitric Oxide Synthase Type II (EC 1.14.13.39) ; Nos2 protein, mouse (EC 1.14.13.39) ; Arg1 protein, mouse (EC 3.5.3.1) ; Arginase (EC 3.5.3.1)
    Language English
    Publishing date 2018-04-17
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2876449-3
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2018015685
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.

    Pandey, Soumya / Nakagawa, Mayumi / Rosenbaum, Eric R / Arnaoutakis, Konstantinos / Hutchins, Laura F / Makhoul, Issam / Milojkovic, Natasha / Cottler-Fox, Michele

    Journal of clinical apheresis

    2015  Volume 30, Issue 1, Page(s) 50–54

    Abstract: ... patients with an ADAMTS13 inhibitor to permit withholding TPE for 48 h after rituximab infusion. ...

    Abstract Thrombotic thrombocytopenic purpura (TTP) results from a congenital or acquired deficiency of the von Willebrand factor (vWF)-cleaving protease ADAMTS13. The disease can be fatal and hence treatment should be initiated promptly. Therapeutic plasma exchange (TPE) remains the standard treatment along with adjunct therapies including steroids and immunosuppressive drugs. Addition of rituximab to TPE has been shown to be beneficial in refractory/relapsing TTP; however, TPE results in removal of rituximab from the circulation requiring more frequent dosing of rituximab to achieve a favorable outcome. The intermediate-purity plasma-derived Factor VIII concentrate (FVIII) Koate® contains the highest amount of ADAMTS13 activity yet reported and has been used successfully in treating congenital TTP. Here we report our experience with addition of this FVIII concentrate to rituximab, corticosteroids and TPE in three TTP patients with an ADAMTS13 inhibitor to permit withholding TPE for 48 h after rituximab infusion.
    MeSH term(s) ADAM Proteins/antagonists & inhibitors ; ADAM Proteins/deficiency ; ADAM Proteins/immunology ; ADAMTS13 Protein ; Adult ; Aged ; Autoantibodies/blood ; Combined Modality Therapy ; Factor VIII/administration & dosage ; Female ; Humans ; Immunosuppressive Agents/administration & dosage ; Male ; Plasma Exchange ; Purpura, Thrombotic Thrombocytopenic/blood ; Purpura, Thrombotic Thrombocytopenic/immunology ; Purpura, Thrombotic Thrombocytopenic/therapy ; Rituximab/administration & dosage ; Young Adult
    Chemical Substances Autoantibodies ; Immunosuppressive Agents ; Rituximab (4F4X42SYQ6) ; Factor VIII (9001-27-8) ; ADAM Proteins (EC 3.4.24.-) ; ADAMTS13 Protein (EC 3.4.24.87) ; ADAMTS13 protein, human (EC 3.4.24.87)
    Language English
    Publishing date 2015-02
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 604912-6
    ISSN 1098-1101 ; 0733-2459
    ISSN (online) 1098-1101
    ISSN 0733-2459
    DOI 10.1002/jca.21348
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1831: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Stem cell mobilization.

    Cottler-Fox, Michele H / Lapidot, Tsvee / Petit, Isabelle / Kollet, Orit / DiPersio, John F / Link, Dan / Devine, Steven

    Hematology. American Society of Hematology. Education Program

    2003  , Page(s) 419–437

    Abstract: ... to undergo clinical testing. In Section II, Dr. Michele Cottler-Fox describes factors predicting the ability ...

    Abstract Successful blood and marrow transplant (BMT), both autologous and allogeneic, requires the infusion of a sufficient number of hematopoietic progenitor/stem cells (HPCs) capable of homing to the marrow cavity and regenerating a full array of hematopoietic cell lineages in a timely fashion. At present, the most commonly used surrogate marker for HPCs is the cell surface marker CD34, identified in the clinical laboratory by flow cytometry. Clinical studies have shown that infusion of at least 2 x 10(6) CD34(+) cells/kg recipient body weight results in reliable engraftment as measured by recovery of adequate neutrophil and platelet counts approximately 14 days after transplant. Recruitment of HPCs from the marrow into the blood is termed mobilization, or, more commonly, stem cell mobilization. In Section I, Dr. Tsvee Lapidot and colleagues review the wide range of factors influencing stem cell mobilization. Our current understanding focuses on chemokines, proteolytic enzymes, adhesion molecules, cytokines and stromal cell-stem cell interactions. On the basis of this understanding, new approaches to mobilization have been designed and are now starting to undergo clinical testing. In Section II, Dr. Michele Cottler-Fox describes factors predicting the ability to mobilize the older patient with myeloma. In addition, clinical approaches to improving collection by individualizing the timing of apheresis and adjusting the volume of blood processed to achieve a desired product are discussed. Key to this process is the daily enumeration of blood CD34(+) cells. Newer methods of enumerating and mobilizing autologous blood HPCs are discussed. In Section III, Dr. John DiPersio and colleagues provide data on clinical results of mobilizing allogeneic donors with G-CSF, GM-CSF and the combination of both as relates to the number and type of cells collected by apheresis. Newer methods of stem cell mobilization as well as the relationship of graft composition on immune reconstitution and GVHD are discussed.
    MeSH term(s) Age Factors ; Algorithms ; Antigens, CD/analysis ; Blood Component Removal/methods ; Cytokines/pharmacology ; Hematopoietic Stem Cell Mobilization/methods ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Treatment Outcome
    Chemical Substances Antigens, CD ; Cytokines
    Language English
    Publishing date 2003-11-04
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2084287-9
    ISSN 1520-4383 ; 1520-4391
    ISSN (online) 1520-4383
    ISSN 1520-4391
    DOI 10.1182/asheducation-2003.1.419
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: The pathobiology of HIV infection.

    Fox, C H / Cottler-Fox, M

    Immunology today

    1992  Volume 13, Issue 9, Page(s) 353–356

    Abstract: ... Fox and Michele Cottler-Fox propose that, as a result of FDC binding of immune-complexed viruses ...

    Abstract The follicular dendritic cells (FDCs) of the germinal center are known to absorb antigens in the form of immune complexes and to express them on the cell surface for long periods of time. Here, Cecil Fox and Michele Cottler-Fox propose that, as a result of FDC binding of immune-complexed viruses, lymphoid organs are the major reservoirs of HIV, and that FDCs play a key role in infection of CD4+ T cells.
    MeSH term(s) Antigen-Antibody Complex/immunology ; CD4-Positive T-Lymphocytes/microbiology ; Dendritic Cells/immunology ; Dendritic Cells/microbiology ; Dendritic Cells/pathology ; HIV Antibodies/immunology ; HIV Antigens/immunology ; HIV Infections/immunology ; HIV Infections/pathology ; Humans ; Lymph Nodes/blood supply ; Lymph Nodes/microbiology ; Lymph Nodes/pathology ; Lymphoid Tissue/immunology ; Lymphoid Tissue/microbiology ; Lymphoid Tissue/pathology ; Models, Biological
    Chemical Substances Antigen-Antibody Complex ; HIV Antibodies ; HIV Antigens
    Language English
    Publishing date 1992-09
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 283214-8
    ISSN 1355-8242 ; 0167-5699 ; 0167-4919
    ISSN (online) 1355-8242
    ISSN 0167-5699 ; 0167-4919
    DOI 10.1016/0167-5699(92)90171-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1601: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 2: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

    Shaughnessy, John D / Zhan, Fenghuang / Burington, Bart E / Huang, Yongsheng / Colla, Simona / Hanamura, Ichiro / Stewart, James P / Kordsmeier, Bob / Randolph, Christopher / Williams, David R / Xiao, Yan / Xu, Hongwei / Epstein, Joshua / Anaissie, Elias / Krishna, Somashekar G / Cottler-Fox, Michele / Hollmig, Klaus / Mohiuddin, Abid / Pineda-Roman, Mauricio /
    Tricot, Guido / van Rhee, Frits / Sawyer, Jeffrey / Alsayed, Yazan / Walker, Ronald / Zangari, Maurizio / Crowley, John / Barlogie, Bart

    Blood

    2006  Volume 109, Issue 6, Page(s) 2276–2284

    Abstract: To molecularly define high-risk disease, we performed microarray analysis on tumor cells from 532 newly diagnosed patients with multiple myeloma (MM) treated on 2 separate protocols. Using log-rank tests of expression quartiles, 70 genes, 30% mapping to ... ...

    Abstract To molecularly define high-risk disease, we performed microarray analysis on tumor cells from 532 newly diagnosed patients with multiple myeloma (MM) treated on 2 separate protocols. Using log-rank tests of expression quartiles, 70 genes, 30% mapping to chromosome 1 (P < .001), were linked to early disease-related death. Importantly, most up-regulated genes mapped to chromosome 1q, and down-regulated genes mapped to chromosome 1p. The ratio of mean expression levels of up-regulated to down-regulated genes defined a high-risk score present in 13% of patients with shorter durations of complete remission, event-free survival, and overall survival (training set: hazard ratio [HR], 5.16; P < .001; test cohort: HR, 4.75; P < .001). The high-risk score also was an independent predictor of outcome endpoints in multivariate analysis (P < .001) that included the International Staging System and high-risk translocations. In a comparison of paired baseline and relapse samples, the high-risk score frequency rose to 76% at relapse and predicted short postrelapse survival (P < .05). Multivariate discriminant analysis revealed that a 17-gene subset could predict outcome as well as the 70-gene model. Our data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions.
    MeSH term(s) Aged ; Chromosome Mapping ; Chromosomes, Human, Pair 1/genetics ; Cohort Studies ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; Models, Genetic ; Multigene Family ; Multiple Myeloma/epidemiology ; Multiple Myeloma/genetics ; Multiple Myeloma/pathology ; Recurrence ; Risk Factors ; Survival Rate
    Language English
    Publishing date 2006-11-14
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2006-07-038430
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top